Related Experiment Video
Updated: Jun 3, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.7K
Advancing drug development in myelodysplastic syndromes
Alain Mina1,2, Kathy L McGraw1,2,3, Lea Cunningham1,2
1Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Blood Advances
|January 9, 2025
Summary
Developing new treatments for myelodysplastic syndromes (MDS) faces challenges in clinical trials. Addressing these issues is key to advancing MDS therapies and improving patient outcomes.
Area of Science:
- Hematology
- Oncology
- Stem Cell Malignancies
Background:
- Myelodysplastic syndromes (MDS) are stem cell cancers with poor prognosis.
- Curative options are limited to stem cell transplantation.
- Recent drug approvals show modest progress, but transformative therapies are lacking.
Purpose of the Study:
- To identify and categorize challenges in MDS drug development.
- To propose strategies for optimizing clinical trial design in MDS.
- To facilitate the advancement of novel MDS therapies.
Main Methods:
- Review and categorization of existing challenges in MDS clinical trials.
- Analysis of criteria for risk stratification, eligibility, and response definitions.
- Discussion of endpoints, functional assessments, and biomarker development.
Main Results:
- Key challenges include risk stratification, response criteria, and endpoint selection.
- Biomarker development and functional assessments require optimization.
- Current trial designs face significant hurdles for drug development.
Conclusions:
- Addressing multifaceted challenges in clinical trial design is crucial for MDS.
- Optimized trial strategies are needed to accelerate the development of effective MDS therapies.
- Improved approaches will enhance therapeutic progress for MDS patients.
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
279
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
279
01:22iPS Cell Differentiation
2.6K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.6K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K